antiangiogenic therapy (4.11, 0.05); inhibits tumor growth (4.11, 0.05); systemic treatments (4.11, 0.05); tie2 expressing monocytes (4.11, 0.05); plasmacytoid dendritic cells (4.11, 0.05). This evidence concerns the gene TEK and neoplasm.